Sector News

Medtronic appoints Madan Krishnan as VP Indian Sub-continent

September 8, 2016
Life sciences

Global medical technology major Medtronic plc has appointed Madan Krishnan as Vice President for Indian sub-continent.

In this role, Krishnan will lead the Medtronic Indian sub-continent business (ISC), which includes India, Sri Lanka, Bangladeshand Nepal, Medtronic plc said in a statement.

Commenting on the development, Medtronic AsiaPacific President Bob White said: “”We see tremendous growth potential in ISC and I have full confidence in Madan’s ability to be an engaged and collaborative industry leader while caring for our employees.”

Krishnan joined Medtronic in 2011. Prior to this appointment, Krishnan was vice president of finance, AsiaPacific (APAC).

Medtronic began its operations in Indiain 1979. Headquartered in Mumbai, the company has offices at Ahmedabad, Bengaluru, Chennai, Cochin, Dhaka, Gurgaon, Hyderabad, Kolkata, New Delhi, Puneand Vadodara.

Source: Business Standard

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach